LIN, RONG HWA,林荣华,林榮華,LIN, LEEWEN,林丽文,林麗文,LIN, SHIH YAO,林士瑶,林士瑤,LEE, SHU HUA,李叔桦,李叔樺
申请号：
TW096120585
公开号：
TWI429658B
申请日:
2007.06.07
申请国别(地区):
TW
年份:
2014
代理人:
摘要：
The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a Leastructure, a Lea-lactose structure, a LNDFH II structure, or a LNT structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.本發明提供新穎抗體,其可專一地結合至非造血性癌症細胞所表現之CD43和CEA上的抗原決定基,但不會專一地結合至白血球或Jurkat細胞所表現之CD43上的抗原決定基,且在不需結合細胞毒素和免疫效應功能的情況下,於結合至該非造血性癌症細胞表面上之抗原決定基後可導致該非造血性癌症細胞的細胞凋亡,其中該抗原決定基包含一醣類構造且該抗體對抗原決定基的結合受到一醣類的抑制,該醣類包含Lea構造、Lea-乳糖構造、LNDFH II構造或LNT構造。此外,本發明亦提供此處所述抗體於診斷和治療的用途。
